News Update

Apr 01, 2001
Pharmaceutical Executive
Pretoria, South Africa-Few people noticed that the ground had begun to crumble under Big Pharma when, after the failed World Trade Organization talks in Seattle, Washington, the Clinton administration indicated that it would take note of the effects of its trade policies on healthcare in developing countries. Multinational companies had hitherto been able to take the support of governments for granted when it came to policing intellectual property, but Clinton's move indicated a major shift in policy. Few noticed, because the rhetoric wasn't immediately matched by reality. In fact, the US government continued to pressure countries whose intellectual property protection seemed too weak. Then the new Bush administration, thought to be an unwavering ally of the pharmaceutical industry, indicated it would continue the Clinton policy.
Apr 01, 2001
Pharmaceutical Executive
Brussels-Two types of mutual recognition procedures are necessary to ensure that generics get to market as quickly as possible, according to the European Generics Medicines Association.
Apr 01, 2001
Pharmaceutical Executive
Bagsvaerd, Denmark-Niche players with good exposure to US markets are showing strong growth, bucking the notion that size is everything in the pharmaceutical industry. And, if it is true that the industry is recession-proof, that situation is unlikely to change, even in the event of a US downturn.
Mar 01, 2001
Pharmaceutical Executive
Brazil}In 1994, the World Bank estimated that 1.2 million Brazilians would be HIV-positive in 2000.
Mar 01, 2001
Pharmaceutical Executive
United States-At this time last year, the United States} supply of tetanus vaccine was easily met by the two companies licensed to produce it there, Aventis Pasteur and Wyeth-Ayerst. But in June 2000, the latter ran into regulatory problems, and FDA seized thousands of substandard doses of acellular pertussis vaccine from the company}s Marietta, Pennsylvania, plant.
Mar 01, 2001
Pharmaceutical Executive
Stirling, UK-Scotia became the first public UK biotechnology company to seek protection from creditors after the European Medicines Evaluation Agency rejected Foscan (temoporfin), the anticancer agent on which its fortunes were pinned.
Mar 01, 2001
Pharmaceutical Executive
Huntingdon, UK-Huntingdon Life Sciences, a contract research organization under siege by animal rights activists, secured its short-term future through a refinancing package offered by overseas institutions.
Mar 01, 2001
Pharmaceutical Executive
Beijing, China-Chinese scientists registered more than 110 patents on genes cloned last year from the human hypothalamus}pituitary}adrenal axis. They profiled the axis} gene expression, cloning more than 300 previously unknown genes discovered during its sequencing.
Mar 01, 2001
Pharmaceutical Executive
New Delhi, India-Anthrax, a disease that most commonly infects livestock, has been diagnosed at an increasing rate in humans in the southern states of India. The disease has been eradicated in the developed world but remains endemic in South India, mostly due to a lack of effective human and animal vaccines.
Mar 01, 2001
Pharmaceutical Executive
Sodertalje, Sweden-After two consecutive years of robust postmerger growth, AstraZeneca is facing a tough 2001. The company recorded a 16 percent increase in pretax profits for 2000, but CEO Tom McKillop advises that this year}s growth will be in the 5}6 percent range when Losec/Prilosec (omeprazole)-the world}s best-selling medicine-goes off patent and the US launch of its successor Nexium (esomeprazole) is delayed.
native1_300x100
lorem ipsum